Oruka Therapeutics, Inc.
ORKA
NASDAQ
Healthcare
$85.21
-8.66%loss today
Market position
Market cap rank
#1747
of 2,614
1-day
-8.66%
1-month
+54.28%
6-month
+181.13%
YTD
+201.41%
1-year
+575.73%
5-year
+107.63%
Key figures
Market cap
$3.19B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-13.1
FY 2025
EPS
-$2.31
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$19.36
Gross margin
0.00%
FY 2025
Operating margin
0.00%
FY 2025
Net margin
0.00%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.34B
FY 2025
EV / EBITDA
-12.70
FY 2025
EV / Sales
0.00
FY 2025
Price / book
2.93
FY 2025
Price / sales
0.00
FY 2025
Earnings yield
-7.63%
FY 2025
FCF yield
-6.40%
FY 2025
Debt / equity
0.00
FY 2025
Current ratio
22.37
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$0
Gross profit
$-83K
Operating income
$-122.05M
EBITDA
$-105.35M
Net income
$-105.43M
Diluted EPS
-$2.31
Shares outstanding
45,614,142
Trading
Open
$91.09
Previous close
$93.29
Day range
$82.23 – $91.78
52-week range
$12.48 – $97.78
50-day avg
$68.72
200-day avg
$41.96
Volume
4,523,803
Avg volume
1,829,340
Beta
-0.40
Price history
+575.73% over 1Y
Compare with peers
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.
Visit websiteCompany info
CEO
Lawrence Otto Klein
IPO date
Aug 8, 1997
Headquarters
Menlo Park, MA, US
Country
US
Fundamentals are annual. Figures labeled with their fiscal year.
